Discovery Labs Reports Preliminary Results From Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
09 juin 2010 07h30 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., June 9, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), reports preliminary results from its Phase 2 clinical trial of Surfaxin® in children with Acute...
Discovery Labs Receives FDA Guidance Regarding Preclinical Program to Gain Surfaxin(R) Approval
08 juin 2010 16h10 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., June 8, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announces today that it has received written guidance from the U.S. Food and Drug Administration (FDA) that...
Discovery Labs Announces Listing Transfer to NASDAQ Capital Market
02 juin 2010 16h05 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., June 2, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq: DSCO), announced today that The Nasdaq Stock Market, LLC has approved Discovery Labs' application to transfer...
Discovery Labs Achieves Key Milestone Towards Potential Surfaxin(R) Approval
19 mai 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 19, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announces today that the revalidation of its optimized fetal rabbit Biological Activity Test (BAT, an...
Discovery Labs' KL4 Surfactant Demonstrates Potential Protective Role for Lung Transplantation in Established Preclinical Model
17 mai 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 17, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that data from a preclinical study using Discovery Labs' KL4 surfactant (lucinactant) in an...
Discovery Labs' Phase 2a Aerosurf(R) Study Published in Journal of Aerosol Medicine and Pulmonary Drug Delivery
14 mai 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 14, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announces the publication of results from its previously-conducted Phase 2a feasibility study of...
Surfaxin LS(TM) Improves Pulmonary Function and Reduces Lung Inflammation in Established Model of Respiratory Distress Syndrome
05 mai 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., May 5, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced that new data regarding Surfaxin LSTM (its novel, lyophilized KL4 surfactant dosage form)...
Discovery Labs' KL4 Surfactant Data to be Presented at Pediatric Academic Societies Annual Meeting and American Thoracic Society International Conference
28 avr. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., April 28, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), announced that new data supporting the unique properties of its KL4 surfactant technology will be...
Discovery Labs Announces Conference Call
28 avr. 2010 07h00 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., April 28, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will be hosting a conference call today, Wednesday, April 28, 2010, at 10:00 AM EDT. Management will...
Discovery Labs Provides Updates on Surfaxin(R), Other Key Programs and First Quarter 2010 Financial Results
27 avr. 2010 18h33 HE
|
Discovery Laboratories, Inc.
WARRINGTON, Pa., April 27, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel synthetic surfactant and aerosol technologies for...